The French biotech said that its lead therapeutic candidate demonstrated the first reduction in HIV...
Up To Date
Latest News
British respiratory disease specialist Verona Pharma plc (VRNA) has raised US-$77.8m (€73,96m) at NASDAQ...
Epigenomics and minority shareholder Cathay Fortune International Company have agreed for Cathay to take over...
Belgian-Dutch antibody developer Argenx N.V. seeks to raise US$74.7m in a US IPO. The company, which is...
Four orphan drugs, three biosimilars, and one monoclonal antibody therapy have been recommended for EU market...
With treatment cost of €1m+ per patient, Glybera was the most expensive therapy ever approved in Europe. Now,...
Share
